Abstract |
Tumor-associated carbohydrate antigen (TACA)-based cancer vaccines achieved promising results, whereas missing the T cell-mediated cellular immune response is still a crucial problem to be solved. Here, we have developed Tn antigen (GalNAc)-modified liposome-encapsulated TLR9 agonist CpG ODN adjuvant as a cancer vaccine. The glyco- liposome vaccines exhibit strong binding ability with an anti-Tn specific antibody and enhance antigen presentation of both bone marrow-derived dendritic cells (BMDCs) and spleen B cells. In vivo immunogenicity studies have demonstrated that the glyco- liposome vaccines can significantly enhance the generation of high anti- Tn antigen antibody titers and further induce a Th1-dependent cellular immune response, evidenced by IFN-γ secretion in an immune coculture of immunized T cells with Tn-expression 4T1 cancer cells. Collectively, our results highlight a liposome-based carbohydrate vaccine as a promising platform, which can simultaneously elicit both humoral and cellular antitumor immunity.
|
Authors | Lintong Yao, Libin Wu, Rujin Wang, Yu Liu, Feifei Luo, Yufei Zhang, Guosong Chen |
Journal | ACS macro letters
(ACS Macro Lett)
Vol. 11
Issue 8
Pg. 975-981
(08 16 2022)
ISSN: 2161-1653 [Electronic] United States |
PMID | 35833848
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Cancer Vaccines
- Carbohydrates
- Liposomes
|
Topics |
- Adjuvants, Immunologic
- Cancer Vaccines
- Carbohydrates
- Immunity, Cellular
- Liposomes
|